Merck & Co., Inc. (MRK) Is Unlikely To Face Antitrust Action For Verona Deal, Says Jim Cramer
Merck & Co., Inc. (NYSE:MRK), one of the largest pharmaceutical companies in the world, has lost 15% year-to-date on the stock market.
Merck & Co. Inc. (MRK)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | HealthInvest Partners AB Anders Hallberg And Carl Bennet | 139,172 | $11,016,856 | +10% | 4.71% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $88.25 | 2,833 | $249,999.98 | 2,933 | 2025-02-06 | Filing | |
| $88.50 | 15,000 | $1,327,500.00 | 16,000 | 2025-02-05 | Filing | |
| $113.68 | 3 | $341.04 | 20,599 | 2023-04-26 | Filing | |
| $105.47 | 136 | $14,343.92 | 20,631 | 2023-03-20 | Filing | |
| $109.20 | 11 | $1,201.20 | 20,495 | 2023-02-21 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $82.76 | 4,262 | $352,723.12 | 7,778 | 2025-04-25 | Filing | |
| $84.09 | 8,500 | $714,744.60 | 30,705 | 2025-02-19 | Filing | |
| $85.34 | 6,000 | $512,056.80 | 24,123 | 2025-02-13 | Filing | |
| $88.76 | 2,361 | $209,550.79 | 7,085 | 2025-02-06 | Filing | |
| $125.50 | 38,291 | $4,805,520.50 | 50,908 | 2024-02-14 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 7,874,766 | $623,366,478 | 0.7% | |
| 2. | 1,878,132 | $148,672,929 | 0.22% | |
| 3. | 1,662,739 | $134,565,540 | 0.22% | |
| 4. | 1,640,300 | $129,747,730 | 0.61% | |
| 5. | 1,036,969 | $82,086,466 | 0.28% |
News See All
Jim Cramer Analyzed These 9 Stocks As He Said Tariffs Are Better Than CIA Coups
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed President Trump's tariffs and their impact on the economy and America's global politics.
Merck & Co., Inc. (MRK)'s CEO Thinks He's Got $50 Billion Of New Drugs, Says Jim Cramer
Merck & Co., Inc. (NYSE:MRK) is one of the largest pharmaceutical companies in the world. The firm has benefited from its KEYTRUDA cancer drug over the past couple of years. However, Merck & Co., Inc.
14 Stocks Jim Cramer Discussed As He Talked About Record Bitcoin Price
In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed the recent Bitcoin price jumps.
Merck Acquires Verona Pharma for $10B to Support Portfolio with COPD Drug Ohtuvayre Ahead of Keytruda Patent Expiration
Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition of UK-based Verona Pharma for ~$10 billion.
UBS Affirms Merck & Co’s (MRK) ‘Buy’ Rating on HPV Vaccine Prospects
Merck & Co., Inc. (NYSE:MRK) is one of the 10 best defensive stocks to buy in a volatile market. On July 2, UBS reiterated a ‘Buy’ rating on the stock and a $105 price target.
10 Best Defensive Stocks to Buy in a Volatile Market
Investor positioning in defensive stock is at its lowest level it has ever been since 2000.
FDA Grants Priority Review for Merck & Co's (MRK) WINREVAIR
Merck & Co., Inc. (NYSE:MRK) is one of the 10 Best Dip Stocks to Buy According to Billionaires. On July 2, Merck & Co., Inc.
Merck & Co (MRK) Announces the Approval of ENFLONSIA
Merck & Co., Inc. (NYSE:MRK) is one of the 11 Best 52-Week Low Stocks to Buy Right Now. On June 26, Merck & Co., Inc.
TD Cowen Maintains Hold Rating on Merck After Enflonsia Vaccine Update
Merck & Co., Inc. (NYSE:MRK) ranks among the best set-it-and-forget-it stocks to buy. On June 27, TD Cowen maintained its Hold rating and $100 price target on Merck & Co., Inc.
Billionaire Hedge Funds
